Modified antisense nucleotides complementary to a section of the human Ha-ras gene

A modified oligodeoxynucleotide comprising SEQ ID NO:1, wherein the modified oligodeoxynucleotide is characterized in that SEQ ID NO:1 has one of the following nucleotide linkage variations;

• (a) 5′-TsAsToToCsCoGoTsCsAsT-3′O—PO2—O—R,
• (b) 5′-TsAsToToCsCoGsToCsAsT-3′O—PO2—O—R,
• (c) 5′-TsAoTsToCsCoGoTsCsAsT-3′O—PO2—O—R,
• (d) 5′-TsAoTsTsCsCoGoTsCsAsT-3′O—PO2—O—R,
• (e) 5′-TsAoTsToCsCsGoTsCsAsT-3′O—PO2—O—R,
• (f) 5′-TsAoTsTsCsCsGoTsCsAsT-3′O—PO2—O—R,
• (g) 5′-TsAsToToCsCsGsToCsAsT-3′O—PO2—O—R,
• (h) 5′-TsAoTsTsCsCsGoTsCsAsT-3′O—PO2—O—R,
• (i) 5′-TsAsTsTsCsCsGoTsCsAsT-3′O—PO2—O—R,
• (j) 5′-TsAsToToCoCsGoTsCsAsT-3′O—PO2—O—R,
• (k) 5′-TsAsTsToCsCsGoTsCsAsT-3′O—PO2—O—R,
• (l) 5′-TsAsTsToCsCoGoTsCsAsT-3′O—PO2—O—R,
• (m) 5′-TsAsToTsCsCoGoTsCsAsT-3′O—PO2—O—R,
• (n) 5′-TsAsToToCsCsGoTsCoAsT-3′O—PO2—O—R,
• (o) 5′-TsAsToTsCsCoGoTsCoAsT-3′O—PO2—O—R,
• (p) 5′-TsAoTsTsCoCsGoTsCoAsT-3′O—PO2—O—R,
• (q) 5′-TsAsTsToCsCsGoToCsAsT-3′O—PO2—O—R,
• (r) 5′-TsAsTsToCoCsGoToCsAsT-3′O—PO2—O—R,
• (s) 5′-ToAoTsToCsCoGoToCsAsT-3′O—PO2—O—R,
• (t) 5′-TsAsTsTsCsCsGoTsCsAsT-3′O—PO2—O—R,
• wherein:
• o means a phosphodiester internucleoside linkage,
• s means a phosphorothioate internucleoside linkage,
• R means a C8-C21 alkyl group, —(CH2—CH2O)n—(CH2)m—CH3 or —CH2CH(OH)CH2O(CH2)q—CH3, wherein n is an integer from 1 to 6, m is an integer from 0 to 20 and q is an integer from 7 to 20 and
• A is 2′-deoxyadenosine,
• G is 2′-deoxyguanosine,
• C is 2′-deoxycytidine and
• T is thymidine.